IMPORTANT SAFETY INFORMATION
WARNING: HEPATOTOXICITY– Severe and sometimes fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function prior to and during treatment. Interrupt and then reduce or discontinue STIVARGA® for hepatotoxicity as manifested by elevated liver function tests or hepatocellular necrosis, depending upon severity and persistence. Continue reading below.
When is it time to act?
INTRODUCING ZERO co-pay
Can be used to register the patient with REACH, which facilitates shipment of STIVARGA once insurance coverage is confirmed or the patient qualifies for the REACH Co-pay Assistance Program.